Gilde Healthcare raises a €100 million lower mid-market healthcare services fund - Gilde Healthcare

Gilde Healthcare raises a €100 million lower mid-market healthcare services fund

January 21, 2015

More capital available for healthcare service providers in the Benelux and Germany

Utrecht, The Netherlands – Gilde Healthcare, the private equity firm dedicated to the healthcare sector, today announces the first and final close of its €100 million Healthcare Services fund, Gilde Healthcare Services II. The new fund will support the growth of healthcare service companies in the Benelux and Germany.

The launch of the new fund comes at a time of healthcare reforms and market developments which leads to increased private entrepreneurship. Healthcare companies increasingly rely on private capital to finance their growth plans as government budgets are tightened and banks have less funds available to finance growth. The new Healthcare Services fund targets specialist clinics, elderly care, primary care, mental health, outsourcing services, medical product suppliers and other healthcare service providers. The fund has a differentiating investment strategy with a focus on companies that aim to provide better care at lower cost.

Jasper van Gorp, Managing Partner for Gilde Healthcare Services:

“We are delighted with the fundraising of our second healthcare services fund and in particular to have the backing of a strong base of blue chip investors. We now have the capital available to support more private healthcare companies. We focus on proven business models and work closely with management teams to further expand these businesses. We are proud to play an active role in improving the quality of healthcare services.“

In the past few years Gilde Healthcare Services has built a portfolio of fast growing companies. For example, the fund supported back pain specialist Fysius in their expansion from 13 to 26 branches, creating nationwide coverage and making specialized, yet affordable care available for patients with back pain. Gilde Healthcare Services also led the spinout of Viroclinics Biosciences from the Erasmus Medical Center. The fund provides hands-on support and capital for their international growth plan. Viroclinics is active in the field of virology diagnostic and contract research services to the pharmaceutical industry. The company has become the market leader in influenza and other infectious diseases, serving nearly all major pharmaceutical companies.

Currently, Gilde Healthcare Services is working on a number of new investment opportunities based on the proven strategy of investing in lower mid-market healthcare services companies with €7.5 million to €75 million in revenues. As per 1 January 2015, Matteo Racca was hired to strengthen the team as investment manager. Matteo has a background in strategy consulting and private equity.

About Gilde Healthcare

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, Massachusetts, United States) is a private equity investor focused on fast growing healthcare businesses. It manages €550 million ($650 million) across five specialized funds. The Gilde Healthcare Services funds I and II focus on healthcare service providers, such as specialist clinics, elderly care, primary care, mental health, outsourcing services, medical product suppliers and other healthcare service providers in the Benelux and Germany. The Gilde Healthcare I, II and III Technology funds target companies developing medicines, medical devices and home & digital health solutions in Europe
and the US. For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.com.

Note to the editor, not for publication:

Contacts at Gilde Healthcare

Jasper van Gorp
Managing Partner

Pieter van der Meer
Managing Partner

+31(0)302192533

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
September 2, 2022